Muscle Invasive Bladder Cancer (MIBC) Clinical Trials

6 recruitingLast updated: June 17, 2026

There are 6 actively recruiting muscle invasive bladder cancer (mibc) clinical trials across 6 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3. Top locations include Beijing, Beijing Municipality, China, Clermont-Ferrand, France, Dijon, France. Updated daily from ClinicalTrials.gov.


Muscle Invasive Bladder Cancer (MIBC) Trials at a Glance

6 actively recruiting trials for muscle invasive bladder cancer (mibc) are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Beijing, Clermont-Ferrand, and Dijon. Lead sponsors running muscle invasive bladder cancer (mibc) studies include Fujian Medical University Union Hospital, ITM Oncologics GmbH, and Johns Hopkins University.

Browse muscle invasive bladder cancer (mibc) trials by phase

Treatments under study

About Muscle Invasive Bladder Cancer (MIBC) Clinical Trials

Looking for clinical trials for Muscle Invasive Bladder Cancer (MIBC)? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Muscle Invasive Bladder Cancer (MIBC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Muscle Invasive Bladder Cancer (MIBC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC

Muscle Invasive Bladder Cancer (MIBC)
Peking University Third Hospital58 enrolled1 locationNCT07647289
Recruiting

Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging

Bladder CancerUrothelial Carcinoma (UC)Muscle Invasive Bladder Cancer (MIBC)+1 more
Oslo University Hospital150 enrolled1 locationNCT07602010
Recruiting
Phase 2

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital25 enrolled12 locationsNCT07296705
Recruiting
Not Applicable

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

Bladder CancerMuscle Invasive Bladder Cancer (MIBC)Muscle Invasive Bladder Cancer Urothelial Carcinoma+1 more
Johns Hopkins University130 enrolled2 locationsNCT07225205
Recruiting
Phase 1Phase 2

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC)Triple Negative Breast Cancer(TNBC)Colorectal Cancer (CRC)+6 more
ITM Oncologics GmbH270 enrolled10 locationsNCT05706129
Recruiting
Phase 3

Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer

Bladder CarcinomaBladder NeoplasmMuscle Invasive Bladder Cancer (MIBC)+2 more
University of Rome Tor Vergata92 enrolled1 locationNCT07067749